Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell (2014) 3.08

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood (2015) 1.50

Resistant mutations in CML and Ph(+)ALL - role of ponatinib. Biologics (2014) 0.99

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep (2015) 0.84

Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us? Cancers (Basel) (2015) 0.80

cFinder: definition and quantification of multiple haplotypes in a mixed sample. BMC Res Notes (2015) 0.79

Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Haematologica (2016) 0.79

Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing. BMC Cancer (2015) 0.78

Best Practices in Chronic Myeloid Leukemia Monitoring and Management. Oncologist (2016) 0.76

Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches. Int J Mol Sci (2016) 0.75

Current developments in molecular monitoring in chronic myeloid leukemia. Ther Adv Hematol (2016) 0.75

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. Br J Cancer (2017) 0.75

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res (2006) 3.47

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood (2011) 3.02

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood (2013) 2.53

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia (2006) 2.49

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica (2008) 2.42

Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov (2007) 2.40

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood (2005) 2.33

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood (2012) 2.01

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood (2007) 1.92

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol (2012) 1.77

A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients. Leuk Res (2007) 1.44

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood (2009) 1.42

Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med (2006) 1.21

An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn (2008) 1.20

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia (2008) 1.17

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia (2005) 1.07

High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations. Leukemia (2007) 1.06

A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia (2006) 1.00

Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. Eur J Cancer (2011) 1.00

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood (2011) 0.98

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia (2011) 0.97

Routine performance and errors of 454 HLA exon sequencing in diagnostics. BMC Bioinformatics (2013) 0.96

BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol (2012) 0.95

Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. Leukemia (2008) 0.90

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica (2012) 0.89

BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol (2009) 0.87

Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR). Leukemia (2008) 0.84

Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on "A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients" by Curvo et al. [Leuk. Res.]. Leuk Res (2008) 0.78

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. Leukemia (2017) 0.75